Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)
Conditions
Interventions
Budesonide oral suspension
Locations
45
United States
Children's Hospital
Birmingham, Alabama, United States
Phoenix Childrens Hospital
Phoenix, Arizona, United States
Del Sol Research Management
Tucson, Arizona, United States
Arkansas Gastroenterology
North Little Rock, Arkansas, United States
Rady Children's Hospital San Diego
San Diego, California, United States
Colorado Children's Hospital
Aurora, Colorado, United States
Start Date
October 5, 2017
Primary Completion Date
April 26, 2022
Completion Date
April 26, 2022
Last Updated
February 19, 2025
NCT06693531
NCT06389994
NCT04394351
NCT03581838
NCT02320981
Lead Sponsor
Shire
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions